PANACEA RESEARCH
The Panacea Bio Chem Sulodexide Research Programme
Panacea Bio Chem investigates sulodexide within a wider vascular-interface biology programme led by Bogdan Dicoias. The objective goes beyond reproducing existing descriptions: from the dual-GAG architecture toward glycocalyx support, vascular barrier restoration, thromboinflammatory regulation, microvascular flow, biochemical stabilisation, formulation architecture, controlled delivery, oxygen and redox management, post-infectious endothelial dysfunction and wider molecular-repair systems.
Nine research pillars
PILLAR 1
Glycocalyx interaction
Incorporation versus protection; reduced degradation; shedding; syndecans; thickness; barrier behaviour. Not every improvement in a measurement is “regeneration” — the mechanism must be distinguished before the word is used.
PILLAR 2
Endothelial permeability
Transendothelial fluid, albumin permeability, junctions, surface exposure and leakage markers. Animal sepsis research is preclinical — it is not evidence of human sepsis efficacy.
PILLAR 3
Thromboinflammation
The coagulation × inflammation intersection. The scientific target is not indiscriminate anticoagulation. It is restoration of controlled interaction at the vascular interface.
PILLAR 4
Fibrinolytic balance
tPA, PAI, fibrin formation and clearance, thrombin generation, clot persistence. Never claimed: elimination of every microclot, destruction of spike protein, removal of vaccine components — those would each require direct experimental evidence that does not exist.
PILLAR 5
Post-viral endothelial dysfunction
A dedicated track: persistent activation, glycocalyx disruption, coagulation markers, permeability, microcirculatory dysfunction, biomarkers, symptom correlation and recovery. The 2025 convalescent RCT is presented accurately — a legitimate vascular research question, not a completed clinical answer.
PILLAR 6
Formulation stability
GAG mixture stability, molecular-weight distribution, sulphation, pH, ionic strength, temperature, oxidation, container interaction, adsorption, filtration, storage, and activity after processing.
PILLAR 7
Composition and characterisation
Fraction percentages, molecular-weight distribution, charge, sulphation, chromatography, potency, impurities, batch consistency, anticoagulant activity and identity testing. “Sulodexide” is a complex biological mixture — characterisation matters.
PILLAR 8
Controlled delivery
Oral, parenteral, local, sustained and targeted formats; protected formulations; cartridge research formats; low-oxygen filling; temperature and materials. No treatment protocols are developed or published here.
PILLAR 9
Functional vascular measurements
Potential endpoints: permeability, glycocalyx imaging, syndecan-1, thrombomodulin, von Willebrand factor, inflammatory markers, nitric-oxide responses, coagulation parameters, fibrinolysis markers, platelet activation, microvascular flow, tissue oxygenation and ECM markers. These remain potential endpoints until actual Panacea protocols and findings are supplied.
Panacea Bio Chem expects to publish new observations, experimental directions and technology developments arising from this programme in the near future.
This statement describes direction, not results. No unpublished experimental findings are claimed on this page; journal entries on the research journal carry explicit evidence labels so that hypotheses are never presented as completed findings.